(E)-AG 556

CAS No. 133550-41-1

(E)-AG 556 ( (E)-Tyrphostin AG 556 )

Catalog No. M27474 CAS No. 133550-41-1

AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 Get Quote
10MG 72 Get Quote
25MG 147 Get Quote
50MG 222 Get Quote
100MG 331 Get Quote
200MG 489 Get Quote
500MG 777 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (E)-AG 556
  • Note
    Research use only, not for human use.
  • Brief Description
    AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
  • Description
    AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
  • Synonyms
    (E)-Tyrphostin AG 556
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    133550-41-1
  • Formula Weight
    336.4
  • Molecular Formula
    C20H20N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#C/C(/C(NCCCCc1ccccc1)=O)=C\c(cc1)cc(O)c1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Qa'dan F, et al. Cinchonain Ib isolated from Eriobotrya japonica induces insulin secretion in vitro and in vivo. J Ethnopharmacol. 2009 Jul 15;124(2):224-7.
molnova catalog
related products
  • Olmutinib

    Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?

  • Dihydroberberine

    Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.

  • Alflutinib

    Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.